Natalie Cusano is an Endocrinology/Metabolic physician affiliated with Queens College. OpenAlex indexes 121 publications with 5,607 citations (h-index 36).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
4 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
86.2%RANK Ligand Inhibitor86%Denosumab100%Part B, office-administered≥111 patientsBisphosphonates0.2%Risedronate Sodium100%Part D<11 patientsMetabolism & gastrointestinal
8.8%GLP-1 receptor agonist3.8%Mounjaro34%Ozempic32%Trulicity32%Rybelsus3%Part D<11 patientsBiguanide (metformin)1.4%Metformin Hcl57%Metformin Hcl Er43%Part D≥29 patients+ 7 more classes in this area
Hormonal (systemic)
3.9%l-Thyroxine3.4%Levothyroxine Sodium76%Synthroid19%Tirosint5%Part D<11 patientsThyroid Hormone Synthesis Inhibitor0.3%Methimazole100%Part D≥14 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2012–2016 per NIH RePORTER. The latest:
- Skeletal Regulation of Cortical and Trabecular Bone by Parathyroid Hormone
Columbia University Health Sciences
FY2016$183,568K23DK095944 - Skeletal Regulation of Cortical and Trabecular Bone by Parathyroid Hormone
Columbia University Health Sciences
FY2015$183,568K23DK095944 - Skeletal Regulation of Cortical and Trabecular Bone by Parathyroid Hormone
Columbia University Health Sciences
FY2014$183,568K23DK095944
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”